Solid tumours

Monoclonal antibody
#ESMO #Innovent #Monoclonal antibodies #Oncology #Solid tumours

Innovent updates ESMO 2024 on mAbs in solid tumours

Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More

#News #Trending News

#Arsenal Biosciences #Cell therapy #Fundraising #Oncology #Solid tumours

Cell therapy developer ArsenalBio raises $325 million

Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds… Read More

#Business & Investment #News

T cell attacking cancer cell
#CDR-Life #Immunotherapy #Oncology #Solid tumours #T cell engagers

CDR-Life progresses pipeline of T cell engagers for solid tumours

CDR-Life has announced new developments to its programme of antibody-based T cell engagers (TCE) targeting intracellular tumour antigens MAGE-A4 and PRAME via the major histocompatibility complex. The first patient has been dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4. Read More

#Cancer Research #News

Liver cancer
#Cell therapy #FDA #Grit Biotechnology #Oncology #Solid tumours

FDA clears genetically engineered TIL therapy for solid tumour trials

Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials… Read More

#Cancer Research #News #Regulatory

Tumour microenvironment
#CV6 Therapeutics #Oncology #Phase I trial #Solid tumours #University of Glasgow

Investigational therapy for advanced cancers enters trials

CV6 Therapeutics has initiated patient dosing in a Phase Ia clinical trial evaluating its investigational first-in-class, specific dUTPase inhibitor CV6-168 + infusional 5-fluorouracil (5-FU). The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced… Read More

#Cancer Research #News

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal… Read More

#News #Regulatory

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

New DDW Highlights podcast: 12 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news highlights this week all centre around significant US Food and Drug Administration… Read More

#News

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

New DDW Highlights vodcast: 12 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The news highlights this week… Read More

#News

#Brain cancer #FDA #hepatitis #PTSD #Regulatory #Solid tumours

This week in drug discovery (5-9 August) 

News round-up for 5-9 August by DDW Senior Digital Content Editor Diana Spencer. The news highlights this week all centre around significant US Food and Drug Administration (FDA) regulatory decisions, including new approvals for drugs for solid tumours, hepatitis B and glioma. The top stories:… Read More

#News

Antibody drug conjugate
#Angiex #Antibody drug conjugate (ADC) #Oncology #Phase I trial #Solid tumours

Antibody-drug conjugate for solid tumours enters Phase I trials

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More

#Cancer Research #News

T cell receptor
#Adaptimmune Therapeutics #Cell therapy #Collaboration #Galapagos #License agreement #Solid tumours

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Cancer research #Funding #Pheon Therapeutics #Solid tumours

$120m raised to develop differentiated ADC pipeline 

Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers.  The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three… Read More

#Business & Investment #Cancer Research #News

Antibody drug conjugate
#Accelerated assessment #Antibody drug conjugate (ADC) #AstraZeneca #Daiichi Sankyo #FDA #Oncology #Solid tumours

First tumour agnostic HER2 directed ADC gets US approval

Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumours. Enhertu has been granted accelerated approval to treat patients who have received prior systemic treatment and… Read More

#News #Regulatory

Antibodies
#Antibodies #Oncology #Phase I trial #Solid tumours

Antibody therapy shows anti-tumour activity in advanced cancer

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More

#Cancer Research #News

GBP pound sterling funding
#Alentis Therapeutics #Curve Therapeutics #Drug discovery #Finance #Funding #Pfizer Ventures #Seed funding #Solid tumours

£40.5 million invested in discovery platform and to advance pipeline 

Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More

#News